Seres Therapeutics, Inc. (MCRB)

Trade MCRB now with
11/5/2019 7:25:11 AM Seres Therapeutics Q3 Loss Per Share $0.23 Vs Loss $0.54 Last Year
6/17/2019 10:08:12 AM Microbiome Says Working Actively With FDA To Develop Guidelines For Application Of Pharmaceutical Development Criteria
6/13/2019 9:34:54 PM Seres Therapeutics Prices Public Offering Of 26.67 Mln Shares At $2.25/shr
6/12/2019 4:28:20 PM Seres Therapeutics Announces Proposed Public Offering Of Common Stock
3/11/2019 9:33:02 AM Seres Therapeutics Announces Three-year Research Collaboration With AstraZeneca
1/15/2019 7:04:27 AM Seres Therapeutics Appoints Eric Shaff As President And CEO
1/8/2019 8:07:13 AM Cygnal Therapeutics Appoints Pearl Huang As CEO
1/3/2019 7:05:22 AM Seres Therapeutics Begins SER-287 Phase 2B ECO-RESET Clinical Study For Ulcerative Colitis
11/8/2018 7:13:13 AM Seres Therapeutics Q3 Net Loss $21.9 Mln Vs. Net Loss $6.9 Mln Last Year
10/22/2018 7:00:41 AM Seres Therapeutics Appoints Kevin Horgan EVP And Chief Medical Officer
8/2/2018 7:18:10 AM Seres Therapeutics Q2 Net Loss $27.8 Mln Vs Loss Of $28.0 Mln Last Year
5/9/2018 7:13:00 AM Seres Therapeutics Q1 Net Loss Widens To $27.9 Mln From $25.5 Mln Last Year
3/14/2018 7:07:43 AM Flagship Pioneering Launches Foghorn Therapeutics With Initial Capital Commitment Of $50 Mln
3/8/2018 7:11:21 AM Seres Therapeutics Q4 Net Loss Widens To $29.0 Mln From $25.3 Mln Last Year
1/31/2018 7:08:01 AM Seres Therapeutics Unveils Appointment Of Eric Shaff To Addl. Role Of COO
3/30/2016 8:30:09 AM FBR Capital Markets Starts Seres Therapeutics, Inc. (MCRB) At Outperform With $40 Price Target